Clinical Practice Guidelines (CPG) on EBMonFHIR
0.8.0-snapshot - ci-build

Clinical Practice Guidelines (CPG) on EBMonFHIR - Local Development build (v0.8.0-snapshot) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Clinical Practice Guidelines (CPG) on EBMonFHIR
... 2 Profiles
... 3 Code Systems
... 4 Value Sets
... 5 Extensions
... 6 Examples
... 7 Downloads
... 8 History
... 9 Artifacts Summary
.... 9.1 Cohorts
.... 9.2 CPGComputablePlanDefinition
.... 9.3 CPGRecommendationDefinition
.... 9.4 CPGShareablePlanDefinition
.... 9.5 CPGStrategyDefinition
.... 9.6 Eligibility Criteria
.... 9.7 Outcome Evidence
.... 9.8 PICO Evidence Variable
.... 9.9 Recommendation Action
.... 9.10 Shareable PlanDefinition
.... 9.11 Assessment Action
.... 9.12 Body Positioning Action
.... 9.13 Certainty of Evidence Rating
.... 9.14 Clinical Practice Guideline
.... 9.15 Drug Administration Action
.... 9.16 Evidence Data Set
.... 9.17 Evidence Synthesis Cohorts
.... 9.18 Guideline Bundle
.... 9.19 Guideline Citation
.... 9.20 Intervention Definition
.... 9.21 Net Effect Estimate
.... 9.22 Outcome Definition
.... 9.23 Outcome Evidence Synthesis
.... 9.24 Recommendation
.... 9.25 Recommendation Citation
.... 9.26 Recommendation Eligibility Criteria
.... 9.27 Recommendation Justification
.... 9.28 Recommendation Plan
.... 9.29 Study Citation
.... 9.30 Study Cohort
.... 9.31 Study Eligibility Criteria
.... 9.32 Study Outcome Evidence
.... 9.33 Action Combination Method
.... 9.34 ArtifactAssessment Publication Status
.... 9.35 ArtifactAssessment Version
.... 9.36 CQFM Artifact Comment
.... 9.37 Dosage Condition
.... 9.38 qualityOfEvidence
.... 9.39 strengthOfRecommendation
.... 9.40 Action Combination Method
.... 9.41 Action Selection Behavior Required
.... 9.42 Allergic Disposition SCT
.... 9.43 Assessment
.... 9.44 Assessment Scales
.... 9.45 Body Positioning SNOMED CT
.... 9.46 Clinical Importance of Outcome
.... 9.47 Cochrane PICO
.... 9.48 Cochrane PICO Intervention
.... 9.49 Cochrane PICO Outcome
.... 9.50 Cochrane PICO Population
.... 9.51 Episode Of Care Type
.... 9.52 Guideline Recommendation Status
.... 9.53 Guideline Stage Classification
.... 9.54 Laboratory Observations
.... 9.55 Mean Difference Type
.... 9.56 Radiologic Finding SCT
.... 9.57 Rating Acceptability
.... 9.58 Rating Benefit And Harms
.... 9.59 Rating Certainty Of Evidence
.... 9.60 Rating Concern Degree
.... 9.61 Rating Consensus
.... 9.62 Rating Equity
.... 9.63 Rating Feasibility
.... 9.64 Rating Preference And Values
.... 9.65 Rating Resources
.... 9.66 Rating Up Rating One Level
.... 9.67 Rating Up Rating Two Levels
.... 9.68 Recommendation Strength
.... 9.69 Relative Effect Type
.... 9.70 Substances SNOMED CT
.... 9.71 Ventilation Observable SCT
.... 9.72 Action Combination Method
.... 9.73 CEOsys Code System
.... 9.74 Clinical Importance of Outcome
.... 9.75 Cochrane Core Ontology
.... 9.76 Cochrane PICO Ontology
.... 9.77 Evidence Certainty Rating
.... 9.78 Evidence To Decision Certainty Rating
.... 9.79 Evidence To Decision Certainty type
.... 9.80 Guideline Stage Classification
.... 9.81 KontaktArtDe
.... 9.82 Recommendation Strength
.... 9.83 SynthesisType
.... 9.84 All-cause mortality
.... 9.85 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V
.... 9.86 Certainty of Evidence for outcome: mortality of Dexamethasone application
.... 9.87 COVID19 Intensive Care Treatment Guideline
.... 9.88 COVID19 Intensive Care Treatment Guideline
.... 9.89 Dexamethasone Application
.... 9.90 Dexamethasone Application
.... 9.91 Dexamethasone Application (Intravenous)
.... 9.92 Dexamethasone Application (Oral)
.... 9.93 Dexamethasone for critically ill COVID-19 patients
.... 9.94 Dexamethasone Recommendation
.... 9.95 Example Assessment Action
.... 9.96 Example Body Positioning Action
.... 9.97 Example Certainty Of Evidence Rating
.... 9.98 Example DrugAdministration Action
.... 9.99 Example Evidence Data Set
.... 9.100 Example Evidence Synthesis Cohorts
.... 9.101 Example Guideline
.... 9.102 Example Guideline Citation
.... 9.103 Example Intervention
.... 9.104 Example Net Effect Estimate
.... 9.105 Example No DrugAdministration Action
.... 9.106 Example Organization
.... 9.107 Example Outcome
.... 9.108 Example Outcome Evidence Synthesis
.... 9.109 Example Recommendation Citation
.... 9.110 Example Recommendation Eligibility Criteria
.... 9.111 Example Recommendation Justification
.... 9.112 Example Recommendation plan
.... 9.113 Example Study Citation
.... 9.114 Example Study Cohort
.... 9.115 Example Study Eligibility Criteria
.... 9.116 Example Study Outcome Evidence
.... 9.117 Guideline Recommendation Example
.... 9.118 Mortality Outcome for Dexamethasone application
.... 9.119 No Dexamethasone Application
.... 9.120 No dexamethasone application for non-ventilated COVID-19 patients
.... 9.121 NO Dexamethasone for moderately ill COVID-19 patients
.... 9.122 Population: COVID19 Non-Ventilated
.... 9.123 Population: COVID19 Ventilated
.... 9.124 recommendation
.... 9.125 Study cohort for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo)
.... 9.126 Study eligibility criteria for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo)
.... 9.127 Systemic corticosteroids for the treatment of COVID-19
.... 9.128 Therapy of hospitalized COVID-19 patients